ESC CONGRESS 2016 EPIGENETICS SYMPOSIUM: KOL VIDEO PRESENTATIONS

As previously announced on Aug. 29th, Resverlogix hosted an Epigenetics Symposium at the European Society of Cardiology (ESC) Congress 2016, titled: “A novel approach for high CV risk patients with diabetes: The potential of epigenetics,” featuring Key Opinion Leaders in cardiovascular disease and diabetes.

Links to video presentations from this event can now be accessed on the PACE website:

Prof. Kausik Ray, Imperial College, London, UK.

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

http://www.pace-cme.org/video.aspx?id=4625

Dr. Jorge Plutzky, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA:

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation:

http://www.pace-cme.org/video.aspx?id=4626

Prof. John Kastelein, Academic Medical Center, Amsterdam, Netherlands.

BET inhibition in cardiovascular disease: A new dawn?

http://www.pace-cme.org/video.aspx?id=4627

The symposium agenda can be accessed here:

http://www.pace-cme.org/d/1890/a-novel-approach-for-high-cv-risk-patients-with-diabetes-the-potential-of-epigenetics

This entry was posted in Diabetes, Events, Video and tagged apabetalone, Atherosclerosis, BET bromodomain inhibitor, biotech, CARDIOVASCULAR, Cardiovascular Disease, CVD, Diabetes, Diabetes Mellitus, DM, epigenetics, Events, glucose, MACE, Resverlogix, RVX, RVX-208 on October 5, 2016 by Resverlogix.